ANAPTYSBIO INC (ANAB) Stock Price, Quote, News and Overview
NASDAQ:ANAB - Nasdaq - US0327241065 - Common Stock
ANAB Quote and Key Statistics
ANAPTYSBIO INC
NASDAQ:ANAB (1/21/2025, 8:00:00 PM)
Premarket: 16.85 -0.03 (-0.18%)16.88
+1.03 (+6.5%)
ANAB Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.57% | ||
| ROE | -196.35% | ||
| Debt/Equity | 0 |
ANAB Performance and Technical Analysis
ANAB Ownership and Analysts
ANAB Latest News and Analysis
Stay updated with the stocks that are on the move in today's pre-market session.
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
See How AnaptysBio Ranks Among Analysts' Top Picks With Strong Buyback Activity
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
About ANAB
Company Profile
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 117 full-time employees. The company went IPO on 2017-01-26. The firm is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The firm's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Company Info
ANAPTYSBIO INC
10770 Wateridge Circle, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Hamza Suria
Employees: 117
Company Website: https://www.anaptysbio.com/
Investor Relations: https://ir.anaptysbio.com/
Phone: 18583626295
ANAB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |